Hp and IL-1 mediated inflammation following intracranial bleeding

  • Research type

    Research Study

  • Full title

    Effect of haptoglobin phenotype on inflammasome activation and IL-1 production within the central nervous system and periphery following intracranial bleeding.

  • IRAS ID

    198967

  • Contact name

    David Brough

  • Contact email

    david.brough@manchester.ac.uk

  • Sponsor organisation

    University of Manchester

  • Duration of Study in the UK

    1 years, 0 months, 1 days

  • Research summary

    Why? We want to know why some types of inflammation can affect recovery after stroke. Intracranial haemorrhage (ICH) accounts for 15% of all strokes and is caused by bleeding into the brain and may affect people of all ages. More than half of those affected do not survive the initial bleed and of those who do, many are left with significant on-going disabilities. There are few treatments for ICH, making research in this area a high priority.

    What? There is evidence that inflammation can influence both early and long-term recovery after ICH. Inflammation is a protective response of our bodies to infection. However, in certain situations inflammation can make disease worse (bad inflammation) and this is known to be the case for ICH. The body has some defences against bad inflammation. As the blood clot breaks down after ICH, it produces a protein called haptoglobin. There are different types of haptoglobin; some of which may actually contribute to bad inflammation. The purpose of this study is to better understand the role of haptoglobin which may help us to identify potential new treatments for targeting inflammation after ICH.

    Who? We will use existing frozen samples of blood plasma and brain fluid (cerebrospinal fluid). This was collected from patients who suffered a brain haemorrhage and participated in research studies at Salford Royal (SRFT). We also use blood samples from people without brain haemorrhage who participated into the same research studies as healthy control volunteers. No new patients will be recruited and no new samples will be collected.

    Where? The research will be conducted at the University of Manchester by other members of the original research team who are scientists rather than hospital doctors.

    How? The analysis will take approximately 12 months (1/3/16-1/3/17).

  • REC name

    North West - Haydock Research Ethics Committee

  • REC reference

    16/NW/0189

  • Date of REC Opinion

    11 Mar 2016

  • REC opinion

    Favourable Opinion